SHR-1918
Phase 3Small molecule
SHR-1918 is one of 75 small molecule programs targeting Hyperlipidemia. It is currently in Phase 3.
3
Indications
7
Total Trials
3
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
130 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Lescol
NovartisPhase 3
Avapro
SanofiPhase 3
Micardis
Boehringer IngelheimPhase 3
Comparator: Statins
Merck & Co.Phase 3
Comparator: Pbo
Merck & Co.Phase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Enlicitide
Merck & Co.Phase 3
Anacetrapib
Merck & Co.Phase 3
Lapaquistat Acetate
TakedaPhase 3
Niacin/laropiprant
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Homozygous Familial Hypercholesterolemia3 trials
Hyperlipidemia1 trial
Efficacy and Safety1 trial
Hypercholesterolemia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR-1918. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details